Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus

Lao Meng-Yi,Ma Tao,Bai Xue-Li,Zhang Xiao-Zhen,Tang Tian-Yu,Liang Ting-Bo
DOI: https://doi.org/10.1016/j.hbpd.2019.04.007
IF: 3.355
2019-01-01
Hepatobiliary & Pancreatic Diseases International
Abstract:To the Editor:Liver transplantation remains the only cure for end-stage liver disease. Tacrolimus is widely used as a first-line immunosuppressive drug to prevent organ rejection after liver transplantation [1–3]. However, tacrolimus has a narrow therapeutic index and wide inter-individual variability in pharmacokinetics, which can result in underimmunosuppression or toxicity. Orally administered tacrolimus is rapidly absorbed from the distal gastrointestinal tract and extensively metabolized in the liver and intestinal
What problem does this paper attempt to address?